JPMorgan Chase & Co. Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target increased by JPMorgan Chase & Co. from $190.00 to $202.00 in a research report report published on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on JAZZ. Piper Sandler reduced their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an overweight rating for the company in a report on Thursday, August 1st. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an equal weight rating for the company in a report on Thursday, August 1st. Robert W. Baird lowered their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating for the company in a research note on Thursday, August 1st. HC Wainwright reaffirmed a buy rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $173.07.

Jazz Pharmaceuticals Stock Down 0.5 %

JAZZ stock opened at $114.36 on Monday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $146.70. The stock’s 50 day simple moving average is $109.05 and its 200 day simple moving average is $113.19. The company has a market cap of $7.21 billion, a P/E ratio of 23.58, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Kovack Advisors Inc. boosted its stake in Jazz Pharmaceuticals by 88.8% in the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after acquiring an additional 26,628 shares during the last quarter. Polaris Capital Management LLC raised its stake in shares of Jazz Pharmaceuticals by 2.2% in the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after buying an additional 27,100 shares during the period. John G Ullman & Associates Inc. bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth $3,631,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth about $106,936,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $380,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.